VERTEX PHARMACEUTICALS INC (VRTX) Stock Price, Quote, News and Overview
NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock - Currency: USD
VRTX Quote, Performance and Key Statistics
VERTEX PHARMACEUTICALS INC
NASDAQ:VRTX (1/24/2025, 8:14:23 PM)
After market: 439.62 0 (0%)439.62
-0.11 (-0.03%)
The current stock price of VRTX is 439.62 USD. In the past month the price increased by 8.48%. In the past year, price increased by 2.2%.
VRTX Latest News, Press Releases and Analysis
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
3 Unstoppable Stocks to Buy in 2025
Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. David Jagielski (Eli Lilly): It may look as though Eli Lilly's stock has peaked given its recent slide, but there's still a lot more room for it to run higher.
First Week of March 21st Options Trading For Vertex Pharmaceuticals (VRTX)
VRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.29 | 16.55B |
Related stock screener links
About VRTX
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 5,400 full-time employees. The firm is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. The company has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The company is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210 US
CEO: Reshma Kewalramani
Employees: 5400
Company Website: https://www.vrtx.com/
Investor Relations: https://investors.vrtx.com/
Phone: 16173416393
VRTX FAQ
What is the stock price of VRTX?
The current stock price of VRTX is 439.62 USD.
What is the symbol for VERTEX PHARMACEUTICALS INC stock?
The exchange symbol of VERTEX PHARMACEUTICALS INC is VRTX and it is listed on the Nasdaq exchange.
On which exchange is VRTX stock listed?
VRTX stock is listed on the Nasdaq exchange.
Is VRTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VRTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VRTX.
Does VRTX stock pay dividends?
VRTX does not pay a dividend.
When does VRTX stock report earnings?
VRTX will report earnings on 2025-02-11, after the market close.
What is the Price/Earnings (PE) ratio of VRTX?
The PE ratio for VRTX is 862. This is based on the reported non-GAAP earnings per share of 0.51 and the current share price of 439.62 USD.
What is the Short Interest ratio of VRTX stock?
The outstanding short interest for VRTX is 1.54% of its float.
VRTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VRTX. When comparing the yearly performance of all stocks, VRTX is a bad performer in the overall market: 69.67% of all stocks are doing better.
VRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to VRTX. VRTX scores excellent on profitability, but there are some minor concerns on its financial health.
VRTX Financial Highlights
Over the last trailing twelve months VRTX reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by -96.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.16% | ||
| ROE | -3.07% | ||
| Debt/Equity | 0.01 |
VRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to VRTX. The Buy consensus is the average rating of analysts ratings from 40 analysts.
For the next year, analysts expect an EPS growth of -96.09% and a revenue growth 10.42% for VRTX